Roche Valganciclovir Phase IV Studies Should Investigate HAART Effect
Executive Summary
Roche valganciclovir Phase IV studies should address the effect of highly active antiretroviral therapy on the drug's efficacy for maintenance therapy in cytomegalovirus retinitis, FDA's Antiviral Drugs Advisory Committee said at its Feb. 27 review of the drug's NDA.